ESR1 and neoplasm: Chakraborty et al. (2021) found that estrogen signaling skewed the tumor environment in models of melanoma towards an immunosuppressive state via the recruitment of myeloid-derived suppressor cells, and that treatment with a selective estrogen receptor down-regulator increased the antitumor efficacy of the immune checkpoint blockade [46].